title: Resistance to acetylsalicylic acid in patients with type 2 diabetes mellitus is associated with lipid disorders and history of current smoking.
abstract: BACKGROUND
  Diabetes mellitus (DM) is an important risk factor for stroke. Acetylsalicylic acid (ASA) is the most frequently used medication for prevention of cardio-cerebral vascular diseases. However, some patients experience ischaemic vascular events despite the use of ASA. This phenomenon is known as "aspirin resistance" (AR). The aim of this study was to assess the prevalence of AR in diabetic patients and search for factors associated with it.
  
  
  METHODS
  The examined group consisted of 96 subjects with diagnosed type 2 DM. Platelet function test was performed by the method of whole blood impedance aggregometry.
  
  
  RESULTS
  Among examined subjects, 51 patients (53.1 %) were sensitive to ASA action (ASA responders) and 45 patients (46.9 %) were resistant to ASA action (ASA non-responders). No association was found between platelet aggregation and gender, age, dose of ASA, known duration of diabetes, BMI, heart rate, mean systolic and diastolic blood pressure, and risk factors except for current smoking (p = 0.030). ASA non-responders were treated shorter with ASA than ASA responders (p = 0.010). The mean total cholesterol (p = 0.020), LDL concentration (p = 0.005), HCT (p = 0.010), WBC (p = 0.030), and PLT (p = 0.050) were significantly higher in ASA non-responders. No association was found between AR and results of other laboratory tests and medications. Multiple logistic regression analysis revealed factors associated with AR: current smoking and LDL concentration higher than 3.5 mmol/l.
  
  
  CONCLUSIONS
  Results of our study did not confirm the association between poor glycaemic control in the diabetic patients and AR. Resistance to ASA in diabetic patients is associated with lipid disorders and history of current smoking.
authors.affiliation: Department of Neurology in Zabrze, Medical University of Silesia, 3-go Maja 13/15, 41-800, Zabrze, Poland, beatamaria.pl@hoga.pl.
authors.forename: B
authors.initials: B
authors.lastname: Łabuz-Roszak
authors.forename: K
authors.initials: K
authors.lastname: Pierzchała
authors.forename: K
authors.initials: K
authors.lastname: Tyrpień
mesh_terms: D000368:Aged; D001241:Aspirin / Q000008:administration & dosage; D002784:Cholesterol / Q000097:blood; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000150:complications*; D004351:Drug Resistance; D005260:Female; D006400:Hematocrit; D006801:Humans; D006949:Hyperlipidemias / Q000150:complications*; D007958:Leukocyte Count; D008077:Lipoproteins, LDL / Q000097:blood; D008297:Male; D008875:Middle Aged; D010976:Platelet Count; D012907:Smoking / Q000009:adverse effects*
chemical_list: D008077:Lipoproteins, LDL; D002784:Cholesterol; D001241:Aspirin